On 6 October, EIP Pharma Inc., a clinical stage therapeutics company focused on treatments for neurodegeneratives diseases, announced that the AscenD-LB Phase II trial met its primary objective of improving cognition in people with mild-to-moderate dementia with Lewy Bodies. The AscenD-LB study is a randomised, double-blind and placebo-controlled trial evaluating the effect of neflamapimod in mild-to-moderate dementia with Lewy Bodies. 91 research participants were enrolled in the US and the Netherlands, they received neflamapimod or placebo with food for 16 weeks.
Findings showed that neflamapimod was well tolerated. The AscenD-LB trial met its primary endpoint by demonstrating a significant improvement on cognition as assessed by the Neuropsychological Test Battery (NTB). In addition, improvements were observed on multiple secondary clinical endpoints. The company is planning to advance development of neflamapimod into Phase III and to present detailed results at the 13th Clinical Trials in Alzheimer’s Disease (CTAD) meeting in November 2020.
